

Amgen Expands its Manufacturing, Research and Development and Commercial Operations

a report by
Amgen

For more than 25 years, Amgen has applied innovative research and development (R&D) to advance important new therapies for serious illness. And, with world-class manufacturing capabilities, Amgen has a long track record of ensuring that these therapies reach the patients who need them. In order to meet on-going patient demand for Amgen's medicines and to support the development of its diverse and robust product pipeline, the company has made significant investments in new manufacturing, R&D and commercial operations in the US and Europe.

Building Capacity to Meet Growing Demand

Since Amgen's founding in 1980, the company has been a pioneer in biologics manufacturing, developing some of the first and most successful processes for large-scale protein production. Over the last five years, Amgen has invested more than US\$3 billion to enhance its manufacturing capabilities in the US and has added more than 4,000 operations jobs in the US since 2001.

Amgen is currently adding a manufacturing plant in Puerto Rico to produce EPOGEN® (Epoetin alfa) and Aranesp® (darbepoetin alfa). In 2005, Amgen received licensure of a NEUPOGEN® (Filgrastim) and Neulasta® (pegfilgrastim) plant in Puerto Rico and Amgen's second Enbrel® (etanercept) plant in Rhode Island, and announced plans to acquire Abgenix, Inc., a leading biopharmaceutical company with a large manufacturing plant in Fremont, California. In addition to the manufacturing facilities in Puerto Rico and Rhode Island, Amgen has two manufacturing plants in Colorado that produce EPOGEN, Aranesp and Kineret® (anakinra), Kepivance™ (palifermin) and pipeline product candidates in late stage clinical development.

In addition, Amgen has been making significant investments in its European operations to support growing clinical and commercial demand for its medicines.

In January 2006, Amgen announced its intention to invest more than US\$1 billion to build a new manufacturing facility in Cork, Ireland. The new facility in Cork will produce products for the growing number of patients in Europe and other parts of the world who benefit from Amgen's vital medicines. The facility in Cork, which the company expects to begin operating in 2009, will employ more than 1,100 people by 2010.

"Amgen is pleased to establish a site in Ireland as part of our ongoing global development and manufacturing expansion," said Fabrizio Bonanni, Senior Vice-President of Manufacturing. "As demand for our products grows in Europe, Amgen requires capacity closer to this important market."

"The company considered several attractive sites in other countries, but chose Ireland due to its thriving biotechnology community, infrastructure to support biologics manufacturing and attractive business climate," said Bonanni. "Our new facilities in Cork will enhance our ability to deliver on Amgen's robust pipeline."

Amgen Expands Development Activities in the US and Europe

In the last four years, Amgen's development pipeline has doubled in size and the company has been adding staff and resources in every area related to clinical development. Currently, tens of thousands of patients in 36 countries are enrolled in clinical trials of Amgen therapies.

Amgen's growth in R&D marks a unique transformation in the company's history. While others in the industry consolidate and reduce workforces, Amgen is launching a major global expansion of its R&D efforts in a number of scientific hubs throughout the world. This global expansion is due to the remarkably robust pipeline that is driving Amgen's growth and helping build a portfolio that rivals any in the industry.

In January 2006, Amgen announced that it intends to build a new R&D center in Uxbridge, UK, and expand its existing R&D operations in Cambridge, UK. In the future, Amgen anticipates R&D expansion in Japan, Australia, Canada and other locations.

"This significant, long-term investment in our global R&D infrastructure underscores the commitment of Amgen to be the world's best human therapeutics company," said Roger Perlmutter, Executive Vice President of R&D.

A Growing Focus on New Markets

In addition to the new European facilities in Cork and Uxbridge, Amgen has selected Zug, Switzerland, as the home of its international commercial operations outside of the US, Canada and Japan. The newly formed Amgen International oversees operations in Europe, Australia and the Middle East.

Amgen expects that it soon will start up activities in Russia, Mexico and Brazil. By the end of the decade, Amgen anticipates expansion of its commercial activities into countries not yet covered in Eastern Europe, Central and Southeast Asia, Africa and Latin America.

“Amgen’s choice of Zug as the headquarters for international commercial operations reflects the outstanding business environment Switzerland offers to biotechnology companies,” said Rolf Hoffmann,

Senior Vice-President of Amgen International Commercial Operations. *“Switzerland is an ideal location from which to further expand Amgen’s commercial operations into new markets. This will accelerate greater patient access to Amgen’s innovative therapies”.* ■

To learn more about Amgen’s pioneering science and vital medicines, and Amgen’s manufacturing facilities and research and development efforts in the US and Europe, visit www.Amgen.com
